Lv41
552 积分 2023-11-16 加入
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China
1小时前
待确认
Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors
2小时前
待确认
Ceritinib Reduces Transendothelial Invasion of Non-small Cell Lung Cancer Cells by Restoring Claudin-10 and Suppressing VEGF-A Signaling
3天前
已完结
Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
11天前
已完结
Chinese expert consensus on perioperative management of patients with operable anaplastic lymphoma kinase-fusion positive non–small-cell lung cancer
14天前
已完结
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
1个月前
已完结
Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases
1个月前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
1个月前
已完结
Antibody–drug conjugates come of age in oncology
2个月前
已完结
Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study
2个月前
已完结
皖公网安备34019202002308
